Suppression of experimental autoimmune myasthenia gravis by intravenous immunoglobulin and isolation of a disease-specific IgG fraction

Annals of the New York Academy of Sciences

Volumn 1110, Issue , 2007, Pages 550-558

  Fuchs, Sara ^a   Feferman, Tali ^a   Zhu, Kai Yun ^a   Meidler, Roberto ^b   Margalit, Raanan ^a   Wang, Ningshan ^a   Laub, Orgad ^b   Souroujon, Miriam C ^a,c  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b Omrix Biopharmaceuticals   (Israel)

^c OPEN UNIVERSITY OF ISRAEL   (Israel)

Author keywords

Experimental autoimmune myasthenia gravis (EAMG); Immunotherapy; Intravenous immunoglobulin (IVIG); Myasthenia gravis (MG)

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL PROLIFERATION; CHROMATOGRAPHY; CONFERENCE PAPER; DISEASE CONTROL; DRUG ACTIVITY; DRUG MECHANISM; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; MYASTHENIA GRAVIS; NONHUMAN; RAT; TH1 CELL;

RATTUS;

EID: 35748958738     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1423.059     Document Type: Conference Paper

References (40)

1. KAZATCHKINE, M.D. & S.V. KAVERI. 2001. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 345: 747-755.
2. DALAKAS, M.C. 2004. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol. Ther. 102: 177-193.
3. LEMIEUX, R., R. BAZIN & S. NERON. 2005. Therapeutic intravenous immunoglobulins. Mol. Immunol. 42: 839-848.
4. SAMUELSSON, A., T.L. TOWERS & J.V. RAVETCH. 2001. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291: 484-486.
5. PASHOV, A. et al. 1998. Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein. Eur. J. Immunol. 28: 1823-1831.
6. ACHIRON, A. et al. 2000. Suppression of experimental autoimmune encephalomyelitis by intravenously administered polyclonal immunoglobulins. J. Autoimmun. 15: 323-330.
7. JORGENSEN, S.H. & P.S. SORENSEN. 2005. Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. J. Neurol. Sci. 233: 61-65.
8. WEISHAUPT, A. et al. 2002. Effects of intravenous immunoglobulins on T cell and oligodendrocyte apoptosis in high-dose antigen therapy in experimental autoimmune encephalomyelitis. Acta Neuropathol. (Berl.) 104: 385-390.
9. SAOUDI, A. et al. 1993. Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int. Immunol. 5: 1559-1567.
10. WADA, J. et al. 2001. Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition. Clin. Exp. Immunol. 124: 282-289.
11. GEORGE, J. et al. 2001. The effect of intravenous immunoglobulins on the progression of experimental autoimmune myocarditis in the rat. Exp. Mol. Pathol. 71: 55-62.
12. JIA, J. & M. POLLOCK. 2000. Treatment of rats with experimental allergic neuritis using high dose immunoglobulin. Chin. Med. J. (Engl.) 113: 1096-1099.
13. SHOENFELD, Y. et al. 2002. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int. Immunol. 14: 1303-1311.
14. GAJDOS, P. et al. 1984. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1: 406-407.
15. EDAN, G. & F. LANDGRAF. 1994. Experience with intravenous immunoglobulin in myasthenia gravis: a review. J. Neurol. Neurosurg. Psychiatry 57(Suppl): 55-56.
16. GAJDOS, P. et al. 1997. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin inmyasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann. Neurol. 41: 789-796.
17. FERRERO, B. & L. DURELLI. 2002. High-dose intravenous immunoglobulin G treatment of myasthenia gravis. Neurol. Sci. 23(Suppl 1): S9-S24.
18. WEGNER, B. & I. AHMED. 2002. Intravenous immunoglobulin monotherapy in long-term treatment of myasthenia gravis. Clin. Neurol. Neurosurg. 105: 3-8.
19. VASSILEV, T. et al. 1999. Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice. Eur. J. Immunol. 29: 2436-2442.
20. ZHU, K.Y. et al. 2006. Intravenous immunoglobulin suppresses experimental myasthenia gravis: immunological mechanisms. J. Neuroimmunol. 176: 187-197.
21. AHARONOV, A. et al. 1977. Immunochemical studies on acetylcholine receptor from Torpedo californica. Immunochemistry 14: 129-137.
22. BLEEKER, W.K., J.L. TEELING & C.E. HACK. 2001. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood 98: 3136-3142.
23. SHI, F.D. et al. 1998. Differential requirements for CD28 and CD40 ligand in the induction of experimental autoimmune myasthenia gravis. Eur. J. Immunol. 28: 3587-3593.
24. IM, S.H. et al. 2001. Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4. J. Immunol. 166: 6893-6898.
25. IM, S.H. et al. 1999. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. J. Clin. Invest. 104: 1723-1730.
26. IM, S.H. et al. 2000. Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis. J. Neuroimmunol. 111: 161-168.
27. WANG, H.B. et al. 2000. Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis. Int. Immunol. 12: 1381-1388.
28. GOLUSZKO, E. et al. 2002. Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis. J. Neuroimmunol. 122: 85-93.
29. DUAN, R.S. et al. 2002. Anti-TNF-alpha antibodies suppress the development of experimental autoimmune myasthenia gravis. J. Autoimmun. 19: 169-174.
30. ACHIRON, A. et al. 1994. Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion. J. Clin. Invest. 93: 600-605.
31. KARACHUNSKI, P.I. et al. 1999. Interleukin-4 deficiency facilitates development of experimental myasthenia gravis and precludes its prevention by nasal administration of CD4+ epitope sequences of the acetylcholine receptor. J. Neuroimmunol. 95: 73-84.
32. BALASA, B. et al. 1998. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis. J. Immunol. 161: 2856-2862.
33. LINK, H. & B.G. XIAO. 2001. Rat models as tool to develop new immunotherapies. Immunol. Rev. 184: 117-128.
34. POUSSIN, M.A. et al. 2000. Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR. J. Neuroimmunol. 111: 152-160.
35. ZHANG, G.X. et al. 2001. Interleukin 10 aggravates experimental autoimmune myasthenia gravis through inducing Th2 and B cell responses to AChR. J. Neuroimmunol. 113: 10-18.
36. HOWARD, M. & A. O'GARRA. 1992. Biological properties of interleukin 10. Immunol. Today 13: 198-200.
37. BALASA, B. et al. 1997. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J. Exp. Med. 186: 385-391.
38. ZHANG, G.X. et al. 1999. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J. Immunol. 162: 3775-3781.
39. GU, D. et al. 1995. Myasthenia gravis-like syndrome induced by expression of interferon gamma in the neuromuscular junction. J. Exp. Med. 181: 547-557.
40. KARACHUNSKI, P.I. et al. 2000. Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice. J. Immunol. 164: 5236-5244.